[go: up one dir, main page]

MX2018005387A - Variantes de fgf21. - Google Patents

Variantes de fgf21.

Info

Publication number
MX2018005387A
MX2018005387A MX2018005387A MX2018005387A MX2018005387A MX 2018005387 A MX2018005387 A MX 2018005387A MX 2018005387 A MX2018005387 A MX 2018005387A MX 2018005387 A MX2018005387 A MX 2018005387A MX 2018005387 A MX2018005387 A MX 2018005387A
Authority
MX
Mexico
Prior art keywords
fgf21
fgf21 variants
relates
particularfor
nash
Prior art date
Application number
MX2018005387A
Other languages
English (en)
Inventor
Langer Thomas
Boscheinen Oliver
Dreyer Matthias
Sommerfeld Mark
Dittrich Werner
Habermann Paul
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2018005387A publication Critical patent/MX2018005387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a variantes de polipéptidos del factor de crecimiento de fibroblastos 21 (FGF21) humano y a moléculas de fusión de estas, así como a moléculas de ácido nucleico que codifican las mismas. Se refiere además a su uso como medicamentos, en particular, para el tratamiento de obesidad, sobrepeso, síndrome metabólico, diabetes mellitus, hiperglucemia, dislipidemia, esteatohepatitis no alcohólica (NASH) y/o aterosclerosis.
MX2018005387A 2015-12-02 2016-12-02 Variantes de fgf21. MX2018005387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306913 2015-12-02
PCT/EP2016/079551 WO2017093465A1 (en) 2015-12-02 2016-12-02 Fgf21 variants

Publications (1)

Publication Number Publication Date
MX2018005387A true MX2018005387A (es) 2018-08-14

Family

ID=54838293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005387A MX2018005387A (es) 2015-12-02 2016-12-02 Variantes de fgf21.

Country Status (14)

Country Link
US (3) US11230582B2 (es)
EP (2) EP3383890A1 (es)
JP (2) JP7028775B2 (es)
KR (1) KR20180083938A (es)
CN (1) CN108602869A (es)
AU (1) AU2016361912A1 (es)
BR (1) BR112018011002A2 (es)
CA (1) CA3006689A1 (es)
IL (1) IL259675A (es)
MX (1) MX2018005387A (es)
RU (1) RU2018123704A (es)
SG (1) SG11201804577RA (es)
TW (1) TW201731867A (es)
WO (1) WO2017093465A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558341A1 (en) 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
AU2018322943B2 (en) * 2017-09-04 2020-06-04 89Bio Ltd. Mutant FGF-21 peptide conjugates and uses thereof
WO2019154189A1 (en) * 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
JP2021528422A (ja) 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN110845596B (zh) * 2019-11-15 2021-09-03 上海交通大学 突变体xSUMO及其相关产品
CN115322794B (zh) * 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2023540663A (ja) * 2020-07-02 2023-09-26 サノフイ Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
CN113354745B (zh) * 2021-07-09 2022-10-04 温州医科大学 一种组合物及规模化生产成纤维细胞生长因子的方法
JP2024527613A (ja) 2021-07-14 2024-07-25 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド 代謝性障害のための融合ポリペプチド
US20240376168A1 (en) * 2021-09-08 2024-11-14 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
KR102774179B1 (ko) * 2021-09-29 2025-03-04 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
CN113980147B (zh) * 2021-11-26 2023-07-28 中国药科大学 一种聚多肽与fgf21融合蛋白突变体及其应用
WO2024153195A1 (en) * 2023-01-18 2024-07-25 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of fusion polypeptides and methods of uses thereof
AU2024242230A1 (en) * 2023-03-31 2025-11-13 Shanghai Duomirui Biotechnology., Ltd. Protein analogue and use thereof
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
MX2007002616A (es) 2004-09-02 2007-05-16 Lilly Co Eli Muteinas de factor de crecimiento de fibroblasto 21.
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA032727B1 (ru) * 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102655877B (zh) 2009-05-05 2017-04-05 安姆根有限公司 Fgf21突变体及其用途
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
US9422353B2 (en) * 2012-06-11 2016-08-23 Eli Lilly And Company Fibroblast growth factor 21 variant, composition , and uses thereof
CN114805531A (zh) * 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
US20250171512A1 (en) 2025-05-29
US11230582B2 (en) 2022-01-25
US20180371041A1 (en) 2018-12-27
JP7028775B2 (ja) 2022-03-02
EP3693382A1 (en) 2020-08-12
BR112018011002A2 (pt) 2018-12-04
KR20180083938A (ko) 2018-07-23
WO2017093465A1 (en) 2017-06-08
IL259675A (en) 2018-07-31
JP2019506138A (ja) 2019-03-07
AU2016361912A1 (en) 2018-07-19
CA3006689A1 (en) 2017-06-08
CN108602869A (zh) 2018-09-28
US20220227825A1 (en) 2022-07-21
TW201731867A (zh) 2017-09-16
RU2018123704A (ru) 2020-01-14
EP3383890A1 (en) 2018-10-10
JP2022068275A (ja) 2022-05-09
SG11201804577RA (en) 2018-06-28
JP7497381B2 (ja) 2024-06-10

Similar Documents

Publication Publication Date Title
MX2018005387A (es) Variantes de fgf21.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
PH12014502766A1 (en) Fibroblast growth factor 21 proteins
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
WO2015048346A3 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
MA49339A (fr) Conjugués insuline-fc à extension oligomère
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
EA201490695A1 (ru) Слитые белки для лечения нарушений метаболизма
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
TN2014000096A1 (en) Fibroblast growth factor 21 variants
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
MX2015008077A (es) Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
TN2015000101A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
IN2014KN02830A (es)
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
WO2015121457A8 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
MY200951A (en) Variants Of Porcine Trypsin
UA107458C2 (uk) Мутанти fgf21 та їх застосування